Skip to main content
Erschienen in: Annals of Surgical Oncology 2/2013

01.02.2013 | Pancreatic Tumors

Intestinal-type and Pancreatobiliary-type Adenocarcinomas: How Does Ampullary Carcinoma Differ from Other Periampullary Malignancies?

verfasst von: Arne Westgaard, MD, PhD, Ewa Pomianowska, MD, Ole Petter F. Clausen, MD, PhD, Ivar P. Gladhaug, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Ampullary carcinomas typically have either intestinal or pancreatobiliary type of differentiation, histopathologically resembling carcinomas of its adjacent tissues (duodenum, bile duct, or pancreas). We evaluated whether the histologic type itself is more important for long-term survival than the fact that the tumor originated in the ampulla.

Methods

Microscopic slides from 207 consecutive pancreatoduodenectomies were reviewed (72 pancreatic, 46 biliary, 61 ampullary, and 28 duodenal adenocarcinomas; 76 intestinal type, 131 pancreatobiliary type). Tumor size, nodal involvement, margin involvement, degree of differentiation, vascular involvement, and perineural growth, as well as overall survival, were compared between different origins of the same histologic type.

Results

Intestinal-type ampullary adenocarcinomas had similar frequency of poor histopathologic factors compared to duodenal adenocarcinomas, and pancreatobiliary-type ampullary adenocarcinomas had similar frequency of poor histopathologic factors compared to pancreatobiliary-type biliary and pancreatic adenocarcinomas. Adjusting for tumor size and nodal involvement, there was no difference in long-term survival between patients with intestinal-type ampullary, duodenal, or biliary and pancreatic tumors (p = 0.79), and there was no difference in long-term survival between patients with pancreatobiliary-type ampullary, biliary, or pancreatic tumors (p = 0.41).

Conclusions

Long-term survival for patients with ampullary carcinomas equals pancreatic, biliary, and duodenal carcinomas when the same histologic type is compared. It can be questioned whether ampullary carcinomas should be regarded as a separate entity in classification of solid tumors. Clinical trials on adjuvant treatments for periampullary carcinomas should stratify by pancreatobiliary type versus intestinal type of histologic differentiation.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Sarmiento JM, Nagomey DM, Sarr MG, Farnell MB. Periampullary cancers: are there differences? Surg Clin North Am. 2001;81:543–55.PubMedCrossRef Sarmiento JM, Nagomey DM, Sarr MG, Farnell MB. Periampullary cancers: are there differences? Surg Clin North Am. 2001;81:543–55.PubMedCrossRef
2.
Zurück zum Zitat Riall TS, Cameron JL, Lillemoe KD, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006;140:764–72.PubMedCrossRef Riall TS, Cameron JL, Lillemoe KD, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006;140:764–72.PubMedCrossRef
3.
Zurück zum Zitat Albores-Saavedra J, Schwartz AM, Batich K, Henson DE. Cancers of the ampulla of Vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol. 2009;100:598–605.PubMedCrossRef Albores-Saavedra J, Schwartz AM, Batich K, Henson DE. Cancers of the ampulla of Vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol. 2009;100:598–605.PubMedCrossRef
4.
Zurück zum Zitat Winter JM, Cameron JL, Olino K, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg. 2010;14:379–87.PubMedCrossRef Winter JM, Cameron JL, Olino K, et al. Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg. 2010;14:379–87.PubMedCrossRef
5.
Zurück zum Zitat Albores-Saavedra J, Henson DE, Klimstra DS. Malignant epithelial tumors of the ampulla. In: Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Washington, DC: Armed Forces Institute of Pathology; 2000. p. 259–316. Albores-Saavedra J, Henson DE, Klimstra DS. Malignant epithelial tumors of the ampulla. In: Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Washington, DC: Armed Forces Institute of Pathology; 2000. p. 259–316.
6.
Zurück zum Zitat Albores-Saavedra J, Hruban RH, Klimstra DS, Zamboni G. Invasive adenocarcinoma of the ampullary region. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon: IARC; 2010. p. 87–91. Albores-Saavedra J, Hruban RH, Klimstra DS, Zamboni G. Invasive adenocarcinoma of the ampullary region. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon: IARC; 2010. p. 87–91.
8.
Zurück zum Zitat Westgaard A, Tafjord S, Farstad IN, et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer. 2008;8:170.PubMedCrossRef Westgaard A, Tafjord S, Farstad IN, et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer. 2008;8:170.PubMedCrossRef
9.
Zurück zum Zitat Schirmacher P, Buchler MW. Ampullary adenocarcinoma—differentiation matters. BMC Cancer. 2008;8:251.PubMedCrossRef Schirmacher P, Buchler MW. Ampullary adenocarcinoma—differentiation matters. BMC Cancer. 2008;8:251.PubMedCrossRef
10.
Zurück zum Zitat Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW. Tumors of the ampulla of Vater: histopathologic classification and predictors of survival. J Am Coll Surg. 2008;207:210–8.PubMedCrossRef Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW. Tumors of the ampulla of Vater: histopathologic classification and predictors of survival. J Am Coll Surg. 2008;207:210–8.PubMedCrossRef
11.
Zurück zum Zitat Bosnan FT. WHO classification of tumours of the digestive system. Lyon: IARC; 2010. Bosnan FT. WHO classification of tumours of the digestive system. Lyon: IARC; 2010.
12.
Zurück zum Zitat Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg. 2012;99:1036–49.PubMedCrossRef Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg. 2012;99:1036–49.PubMedCrossRef
13.
Zurück zum Zitat Carpelan-Holmstrom M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005;54:385–7.PubMedCrossRef Carpelan-Holmstrom M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut. 2005;54:385–7.PubMedCrossRef
14.
Zurück zum Zitat Westgaard A, Laronningen S, Mellem C, et al. Are survival predictions reliable? Hospital volume versus standardisation of histopathologic reporting for accuracy of survival estimates after pancreatoduodenectomy for adenocarcinoma. Eur J Cancer. 2009;45:2850–9.PubMedCrossRef Westgaard A, Laronningen S, Mellem C, et al. Are survival predictions reliable? Hospital volume versus standardisation of histopathologic reporting for accuracy of survival estimates after pancreatoduodenectomy for adenocarcinoma. Eur J Cancer. 2009;45:2850–9.PubMedCrossRef
15.
Zurück zum Zitat Westgaard A, Clausen OPF, Gladhaug IP. Survival estimates after pancreatoduodenectomy skewed by non-standardized histopathology reports. APMIS. 2011;119:689–700.PubMedCrossRef Westgaard A, Clausen OPF, Gladhaug IP. Survival estimates after pancreatoduodenectomy skewed by non-standardized histopathology reports. APMIS. 2011;119:689–700.PubMedCrossRef
16.
Zurück zum Zitat Westgaard A, Schjolberg AR, Cvancarova M, Eide TJ, Clausen OPF, Gladhaug IP. Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. Histopathology. 2009;54:337–47.PubMedCrossRef Westgaard A, Schjolberg AR, Cvancarova M, Eide TJ, Clausen OPF, Gladhaug IP. Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. Histopathology. 2009;54:337–47.PubMedCrossRef
17.
Zurück zum Zitat Kim WS, Choi DW, Choi SH, Heo JS, You DD, Lee HG. Clinical significance of pathologic subtype in curatively resected ampulla of Vater cancer. J Surg Oncol. 2012;105:266–72.PubMedCrossRef Kim WS, Choi DW, Choi SH, Heo JS, You DD, Lee HG. Clinical significance of pathologic subtype in curatively resected ampulla of Vater cancer. J Surg Oncol. 2012;105:266–72.PubMedCrossRef
18.
Zurück zum Zitat Romiti A, Barucca V, Zullo A, et al. Tumors of ampulla of Vater: a case series and review of chemotherapy options. World J Gastrointest Oncol. 2012;4:60–7.PubMedCrossRef Romiti A, Barucca V, Zullo A, et al. Tumors of ampulla of Vater: a case series and review of chemotherapy options. World J Gastrointest Oncol. 2012;4:60–7.PubMedCrossRef
19.
Zurück zum Zitat Amptoulach S, Josefsson A, Kavantzas N, Kalaitzakis E. Adenocarcinoma of the ampulla of Vater: does the histopathologic type matter? Scand J Gastroenterol. 2011;46:1401–3.PubMedCrossRef Amptoulach S, Josefsson A, Kavantzas N, Kalaitzakis E. Adenocarcinoma of the ampulla of Vater: does the histopathologic type matter? Scand J Gastroenterol. 2011;46:1401–3.PubMedCrossRef
20.
Zurück zum Zitat Kimura W, Futakawa N, Yamagata S, et al. Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res. 1994;85:161–6.PubMedCrossRef Kimura W, Futakawa N, Yamagata S, et al. Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res. 1994;85:161–6.PubMedCrossRef
21.
Zurück zum Zitat Ampulla of Vater. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A, editors. AJCC cancer staging manual. 7th edition. Chicago: Springer; 2010. p. 235–40. Ampulla of Vater. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A, editors. AJCC cancer staging manual. 7th edition. Chicago: Springer; 2010. p. 235–40.
22.
Zurück zum Zitat Frierson HF Jr. The gross anatomy and histology of the gallbladder, extrahepatic bile ducts, Vaterian system, and minor papilla. Am J Surg Pathol. 1989;13:146–62.PubMedCrossRef Frierson HF Jr. The gross anatomy and histology of the gallbladder, extrahepatic bile ducts, Vaterian system, and minor papilla. Am J Surg Pathol. 1989;13:146–62.PubMedCrossRef
23.
Zurück zum Zitat Verbeke CS. Resection margins and R1 rates in pancreatic cancer—are we there yet? Histopathology. 2008;52:787–96.PubMedCrossRef Verbeke CS. Resection margins and R1 rates in pancreatic cancer—are we there yet? Histopathology. 2008;52:787–96.PubMedCrossRef
24.
Zurück zum Zitat Kohler I, Jacob D, Budzies J, et al. Phenotypic and genotypic characterization of carcinomas of the papilla of Vater has prognostic and putative therapeutic implications. Am J Clin Pathol. 2011;135:202–11.PubMedCrossRef Kohler I, Jacob D, Budzies J, et al. Phenotypic and genotypic characterization of carcinomas of the papilla of Vater has prognostic and putative therapeutic implications. Am J Clin Pathol. 2011;135:202–11.PubMedCrossRef
25.
Zurück zum Zitat Albores-Saavedra J, Simpson K, Dancer YJ, Hruban R. Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas. Ann Diagn Pathol. 2007;11:3–9.PubMedCrossRef Albores-Saavedra J, Simpson K, Dancer YJ, Hruban R. Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas. Ann Diagn Pathol. 2007;11:3–9.PubMedCrossRef
26.
Zurück zum Zitat Pour PM, Pandey KK, Batra SK. What is the origin of pancreatic adenocarcinoma? Mol Cancer. 2003;2:13.PubMedCrossRef Pour PM, Pandey KK, Batra SK. What is the origin of pancreatic adenocarcinoma? Mol Cancer. 2003;2:13.PubMedCrossRef
27.
Zurück zum Zitat Albores-Saavedra J, Henson DE, Klimstra DS. Dysplasia, carcinoma in situ, and invasive carcinoma of the extrahepatic bile ducts. In: Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Washington, D.C.: Armed Forces Institute of Pathology; 2000. p. 191–215. Albores-Saavedra J, Henson DE, Klimstra DS. Dysplasia, carcinoma in situ, and invasive carcinoma of the extrahepatic bile ducts. In: Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Washington, D.C.: Armed Forces Institute of Pathology; 2000. p. 191–215.
28.
Zurück zum Zitat de Jong MC, Tsai S, Cameron JL, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010;102:256–63.PubMedCrossRef de Jong MC, Tsai S, Cameron JL, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010;102:256–63.PubMedCrossRef
29.
Zurück zum Zitat Kurosaki I, Minagawa M, Kitami C, Takano K, Hatakeyama K. Hepatic resection for liver metastases from carcinomas of the distal bile duct and of the papilla of Vater. Langenbecks Arch Surg. 2011;396:607–13.PubMedCrossRef Kurosaki I, Minagawa M, Kitami C, Takano K, Hatakeyama K. Hepatic resection for liver metastases from carcinomas of the distal bile duct and of the papilla of Vater. Langenbecks Arch Surg. 2011;396:607–13.PubMedCrossRef
31.
Zurück zum Zitat Furuse J, Takada T, Miyazaki M, et al. Guidelines for chemotherapy of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg. 2008;15:55–62.PubMedCrossRef Furuse J, Takada T, Miyazaki M, et al. Guidelines for chemotherapy of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg. 2008;15:55–62.PubMedCrossRef
32.
Zurück zum Zitat Struck A, Howard T, Chiorean EG, Clarke JM, Riffenburgh R, Cardenes HR. Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival. J Surg Oncol. 2009;100:144–8.PubMedCrossRef Struck A, Howard T, Chiorean EG, Clarke JM, Riffenburgh R, Cardenes HR. Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival. J Surg Oncol. 2009;100:144–8.PubMedCrossRef
33.
Zurück zum Zitat Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S. Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2006;66:514–9.PubMedCrossRef Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S. Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2006;66:514–9.PubMedCrossRef
34.
Zurück zum Zitat Narang AK, Miller RC, Hsu CC, et al. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital—Mayo Clinic collaborative study. Radiat Oncol. 2011;6:126.PubMedCrossRef Narang AK, Miller RC, Hsu CC, et al. Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital—Mayo Clinic collaborative study. Radiat Oncol. 2011;6:126.PubMedCrossRef
35.
Zurück zum Zitat Lazaryan A, Kalmadi S, Almhanna K, Pelley R, Kim R. Predictors of clinical outcomes of resected ampullary adenocarcinoma: a single-institution experience. Eur J Surg Oncol. 2011;37:791–7.PubMedCrossRef Lazaryan A, Kalmadi S, Almhanna K, Pelley R, Kim R. Predictors of clinical outcomes of resected ampullary adenocarcinoma: a single-institution experience. Eur J Surg Oncol. 2011;37:791–7.PubMedCrossRef
36.
Zurück zum Zitat Neoptolemos JP, Moore MJ, Cox TF, et al. Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of Vater. J Clin Oncol. 2011;29(Suppl):LBA4006. Neoptolemos JP, Moore MJ, Cox TF, et al. Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of Vater. J Clin Oncol. 2011;29(Suppl):LBA4006.
Metadaten
Titel
Intestinal-type and Pancreatobiliary-type Adenocarcinomas: How Does Ampullary Carcinoma Differ from Other Periampullary Malignancies?
verfasst von
Arne Westgaard, MD, PhD
Ewa Pomianowska, MD
Ole Petter F. Clausen, MD, PhD
Ivar P. Gladhaug, MD, PhD
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2603-0

Weitere Artikel der Ausgabe 2/2013

Annals of Surgical Oncology 2/2013 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.